J Cancer 2018; 9(21):3904-3911. doi:10.7150/jca.26360 This issue Cite

Research Paper

Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis

Hai Zhong, Yingying Qian, Surong Fang, Ying Wang, Yun Tang, Wei Gu

Department of Respiration, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China.

Citation:
Zhong H, Qian Y, Fang S, Wang Y, Tang Y, Gu W. Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis. J Cancer 2018; 9(21):3904-3911. doi:10.7150/jca.26360. https://www.jcancer.org/v09p3904.htm
Other styles

File import instruction

Abstract

Background: The prognostic role of plasma fibrinogen in lung cancer remains controversial. The aim of this meta-analysis was to assess the prognostic value of plasma fibrinogen in lung cancer.

Methods: We performed a systematic literature search to identify eligible studies in PubMed, Embase and the Cochrane Library database. The hazard ratios (HR) and their 95% confidence intervals (CI) were collected from these eligible studies and were used to assess the relationship between plasma fibrinogen and lung cancer.

Results: A total of 16 studies including 6,881 patients were selected in this meta-analysis. The results showed that elevated plasma fibrinogen in lung cancer patients was correlated with poor overall survival (OS) (HR = 1.38, 95% CI: 1.22-1.55, P < 0.001) and disease-free survival (DFS) / progress-free survival (PFS). (HR = 1.29, 95% CI: 1.01-1.65, P = 0.042). When stratified by cut-off value for OS and DFS/PFS, there was no significant heterogeneity. And the results of “cut-off value ≥ 400mg/dl” group showed that the high level of fibrinogen in serum was associated with worse OS and DFS/PFS of lung cancer. In further subgroup analysis by tumor histology, high plasma fibrinogen was also associated with worse OS in non-small cell lung cancer (NSCLC) (HR = 1.32, 95% CI: 1.14-1.53, P < 0.001). However, there was no significant association between high plasma fibrinogen and poor DFS in NSCLC patients (HR = 1.24, 95% CI: 0.97-1.57, P = 0.08). The Egger's regression test indicated evidence of publication bias for DFS/PFS.

Conclusions: Elevated plasma fibrinogen, particularly defined as a plasma fibrinogen concentration of ≥ 400mg/dl, could be a promising indicator for worse OS in lung cancer patients, including NSCLC.

Keywords: Fibrinogen, Lung cancer, Non-small cell lung cancer, Prognosis, Meta-analysis


Citation styles

APA
Zhong, H., Qian, Y., Fang, S., Wang, Y., Tang, Y., Gu, W. (2018). Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis. Journal of Cancer, 9(21), 3904-3911. https://doi.org/10.7150/jca.26360.

ACS
Zhong, H.; Qian, Y.; Fang, S.; Wang, Y.; Tang, Y.; Gu, W. Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis. J. Cancer 2018, 9 (21), 3904-3911. DOI: 10.7150/jca.26360.

NLM
Zhong H, Qian Y, Fang S, Wang Y, Tang Y, Gu W. Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis. J Cancer 2018; 9(21):3904-3911. doi:10.7150/jca.26360. https://www.jcancer.org/v09p3904.htm

CSE
Zhong H, Qian Y, Fang S, Wang Y, Tang Y, Gu W. 2018. Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis. J Cancer. 9(21):3904-3911.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image